Industry Trends

Loading...

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More



Virtify’s Content-Centric Solutions Build Efficiency by Repurposing Data



Loading...

By Ann Neuer

August 24, 2009 | Smart life sciences companies anxious to compress clinical development timelines are moving from a document-centric workflow to a content-centric environment. So says Stephen Bergson, executive vice president, commercial operations of Virtify, a provider of enterprise content compliance solutions.

Stephen_Bergson
Stephen Bergson
“The industry is realizing that document management systems produce static documents that are cumbersome and don’t allow for ready re-use. By moving to a content management environment, you can use, re-use and repurpose compliant content across the enterprise instead of developing the same information over and over again,” Bergson explains.

He is referring to the trend that along the continuum—from discovery to clinical trials to post-approval commercialization—sponsors are seeking to leverage content by intelligently tagging it and simply lifting it from a central data repository that is created throughout a product’s lifecycle. With that capability, data only has to be developed once and it can be re-used for any number of upstream and downstream purposes. For example, existing information can flow into structured product labeling (SPL) documents, electronic common technical documents (eCTD), and be extrapolated for manufacturing standard operating procedures (SOPs). In addition, if documents have changed since originally created, the user is notified of those changes, and only the latest versions are applied.

Being able to leverage content across the enterprise has real ramifications for speeding product development and cutting costs associated with pre- and post-marketing regulatory submissions. Research suggests that approximately 26% of the cost of bringing new drugs to market is linked to creating content in a compliant manner, so any effort to reduce that percentage will have a positive impact on the bottom line. Bergson remarks, “We believe that with effective re-use of compliant content, we can drop that figure by an order of magnitude.”

Mandates from various regulatory agencies across the globe and greater acceptance of standards are driving the move to compliant content-centric systems. Bergson points to factors such as Health Level 7 (HL7) standards, the Information Technology Plan in the Prescription Drug User Fee Act IV (PDUFA), and the European Medicines Agency’s (EMEA) mandatory use of the eCTD for submissions using the Centralised Procedure, starting January 2010. In addition, required adverse event reporting begins in September 2009, as stated in Section 801(a) of the Food and Drug Administration Amendments Act (FDAAA); and there is the upcoming regulated product submission standard.

To address this complex regulatory environment and to streamline re-use of content, Virtify recently launched Virtx, a Web-based, collaborative enterprise content compliance suite that the company claims is the industry’s first. Virtx offers end-to-end solutions through a series of modules that are out-of-the-box ready, but are also configurable. The Virtx modules include SPL, eCTD, Clinical Trial Disclosure System (CTDS), Upcoming Standards Support, and enterprise eCompliance products that automate collaborative document authoring, submissions tracking, and other functions. The suite has an extensible markup language (XML) backbone, uses Web 2.0 architecture and offers a user-friendly interface that is presented in a familiar Microsoft Word-like format.

With the September 27 start date for FDA’s required adverse event reporting on www.clinicaltrials.gov, and with the anticipation that other regulatory agencies will require this same function, there is particular interest in the Clinical Trial Disclosure System module. “CTDS is hot right now with all of the clinical trial mandates and directives coming from regulators,” Bergson comments.

Repurposing content takes the market in a promising direction. According to Bergson, “Clients are realizing that it is costing them a fortune to develop documents and then have them go into a static environment. With life science mandates extending out to 2015, and with new mandates being developed, transitioning out of a static-document world into a content-centric world is where the industry is going.”

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

oracle_RDC
Remote Data Capture:Acquisition and Analysis
Sponsored by Oracle

See why Electronic Data Capture (EDC) is gaining traction in the pharmaceutical
clinical trials arena. Today approximately half of all clinical trials are conducted
electronically, and the figure is rapidly rising. Report includes contributions from
Oracle Health Sciences, Pfizer, PPD, and C3i.

 



oracle20723
The Role of Analytics in Transforming Healthcare
Sponsored by Oracle

Sharing many of the data challenges and opportunities faced by Healthcare, the Life Sciences industry remains focused on delivering new, innovative therapies and solutions to patients in a cost effective, timely and safe way. With spiraling R&D costs, new methods such as adaptive trials, and never ending need for deep pharmacovigilance, the Life Sciences companies that effectively use analytics to explore, monitor and optimize their business will rapidly become the new leaders.

Oracle’s strategy—built upon Enterprise Health Analytics and Health Data Warehouse Foundation—provides a powerful, practical, and extensible approach to delivering the IT analytics infrastructure required to confront the worldwide healthcare challenge.



pegasystems
BPM-Based Case Management Approach to Optimizing Clinical Trial Efficiency
Sponsored by Pegasystems

Business Process Management (BPM) software offers liberation in the planning and management of clinical trials today. SmartBPM provides the components for automating critical clinical trial processes ranging from protocol development and patient enrollment to site management and investigator payments. Advantages are:

  • Potentially stunning return on investment at multiple levels.
  • A 500%, or better, increase in application development time by directly executing business requirements
  • Improved customer retention
  • A 50% possible reduction in training time

Discovered is opportunity to enhance relationships with investigators, subjects, and regulators while bringing momentum to a technology-impaired study startup phase. Learn more about SmartBPM in this complimentary white paper.



Life Science Webcasts & Podcasts

Bio-IT World & CHI

Impact of the 1000 Genomes Project on the Next Wave of Pharmacogenomic Discovery
1000genomeInterview with M. Eileen Dolan, Ph.D., Professor, Medicine, University of Chicago and Speaker at Next-Generation Sequencing Data Management, September 27-29, 2010, Providence, RI  

The 1000 Genomes Project aims to provide detailed genetic variation data on >1000 genomes from worldwide populations using the next-generation sequencing technologies. Some of the samples utilized for the 1000 Genomes Project are the International Hap-Map samples that are composed of lymphoblastoid cell lines (LCLs) derived from individuals of different world populations. The detailed map of human genetic variation promised by the 1000 Genomes project will allow a more in-depth analysis of the contribution of genetic variation to drug response. Future studies utilizing this new resource can greatly enhance our understanding of the genetic basis of drug response and other complex traits.


Download Now 



More Podcasts

Job Openings

mskc logo
Software Engineer – Computational Biology Center

Memorial Sloan-Kettering Cancer Center seeks an Engineer to design and develop complex data analysis systems in support of cancer genomics research projects at the Computational Biology Center. Qualified candidate will have a BA, 5+ years of software development experience and expert knowledge of Java, SQL, and HTML.

Apply: www.mskcciscareers.org.  Equal opportunity and affirmative action employer.

Loading...

For reprints and/or copyright permission, please contact The YGS Group, 3650 West Market Street, York, PA;

(717) 505-9701 ext. 125, or via email to Ashley.Zander@theYGSgroup.com.